Latest Conference Articles

Family-friendly format empowers continuing education.

Marta Pazos, MD, PhD, examined the role of optical coherence tomography, artificial intelligence, and clinical evaluation in early glaucoma management.

Steffen Hamann, PhD, FEBO, FRCOphth, discusses how optic disc drusen can mimic glaucoma and discussed evolving imaging and research strategies.

Andrew Tatham, MD, MBA, FRCOphth, FEBO, outlines the role of micro-invasive glaucoma surgery alongside established glaucoma procedures, focusing on safety, patient selection, and future directions.

AI is reshaping clinical practice in retinal imaging and workflow optimization, according to Priv.-Doz. Dr. med. Jan H. Terheyden, FEBO.

Prof. Dr. Luís Abegão Pinto outlines how real-world datasets can improve artificial intelligence accuracy, reduce bias, and support clinical decision-making at scale.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

Prof. Dr. med. Wolf A. Lagrèze highlights the clinical role, limitations, and future potential of optical coherence tomography in glaucoma and neuro-ophthalmic disease.

Ahead of the 2nd International Glaucoma Symposium in Mainz, Germany, Stephan Schulz of Heidelberg Engineering outlines how the program blends everyday clinical challenges with advances in AI, imaging, and surgery.

This one-day symposium on January 31, 2026, will bring together clinicians and experts at the University Eye Clinic in Mainz to discuss optic neuropathies and diagnostic trends.

The January 31, 2026, conference in Mainz, Germany, will focus on advances in optic neuropathy diagnosis, artificial intelligence applications, and surgical perspectives

US and international glaucoma specialists will converge in Mainz, Germany, on 31 January 2026, to map the next era of glaucoma care—covering AI diagnostics, optic neuropathy evaluation, and modern surgical approaches.

At the 2nd International Glaucoma Symposium on 31 January 2026, leading clinicians and researchers will share cutting-edge insights on modern surgical techniques, optic neuropathy assessment, and artificial intelligence-driven diagnostics.

The pandemic reshapes treatment intervals for neovascular AMD, revealing flexible strategies that maintain visual outcomes and enhance patient care.

Harvard researchers used data to shed light on pediatric neurotrophic keratopathy, revealing key insights into prevalence, vision outcomes, and treatment approaches.

Explore early MacTel diagnosis with OCT/FA, who qualifies for Encelto implant, and how costs, reimbursement, and surgery shape timely retina care.

Sahar Bedrood, MD, PhD; Inder Paul Singh, MD; and AnnMarie Hipsley, DPT, PhD, recount moments that blended professional milestones with mentorship and legacy.

The value of attending industry meetings at the beginning of a career in ophthalmology.

Discover key insights from the AAO 2025 meeting, highlighting advancements in real-world data, gene therapies, multitargeting treatments, and AI in retina care.

The EU-ROP registry revolutionizes retinopathy of prematurity management, offering insights into treatment variations and outcomes across Europe.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

Explore the evolving challenges and insights in long-term follow-up for pediatric gene therapy, focusing on data integrity, ethical considerations, and patient retention.

AI revolutionizes retinal care, enhancing diagnosis, monitoring, and treatment through innovative technologies and collaborative efforts in ophthalmology.

Dr. Curcio highlights volume electron microscopy evidence from a preterm-born adult retina reveals unexpected Müller glial diversity and implications for foveal development.

Research reveals how COVID-19 disrupted anti-VEGF treatment schedules, yet flexible regimens maintain visual outcomes for neovascular AMD patients.

Dr. Quan Dong Nguyen presents interim data from the phase 3 DRAGON study on a potential first therapy for adolescent Stargardt disease.

Explore the challenges and insights in long-term follow-up of paediatric gene therapy, focusing on data integrity, patient retention, and ethical considerations.

Guest lecturer explores the emerging frontiers in ROP therapy and the evolving ethical, clinical, and technological considerations.